Binding of cosalane - A novel highly lipophilic anti-HIV agent - To albumin and glycoprotein

Kameswara R. Kuchimanchi, Mahmoud Ahmed, Thomas P. Johnston, Ashim K. Mitra

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Cosalane is a potent inhibitor of HIV replication with multiple sites of action. The purposes of this study were to (a) determine the extent and nature of cosalane binding to mucin, α1-acid glycoprotein (AAG), plasma, and human (HSA) and bovine serum (BSA) albumin, and (b) determine the primary site(s) of cosalane binding to HSA. Plasma protein binding of cosalane was studied by a gel filtration technique. Cosalane binding to HSA was also determined in the presence of salicylic acid. Competitive inhibition studies were conducted using warfarin, digitoxin, and diazepam to determine the primary HSA binding site(s) of cosalane. The drug was bound extensively to HSA and BSA and required 500-550 moles to saturate 1 mole of protein. Stoichiometries of cosalane binding to α1-acid glycoprotein (AAG) and mucin were between 30 and 50 mol/mol of either glycoprotein. The binding isotherm deviated from a rectangular hyperbola, suggesting self-association of the ligand. Salicylic acid decreased cosalane binding to HSA by one order of magnitude. Inhibition studies of cosalane to HSA revealed that the compound binds primarily to warfarin site with a Ki of 1.24 ± 0.24 nM. In summary, cosalane binds extensively to serum albumins and to a lesser extent to both AAG and mucin.

Original languageEnglish (US)
Pages (from-to)659-666
Number of pages8
JournalJournal of Pharmaceutical Sciences
Volume90
Issue number5
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

cosalane
Anti-HIV Agents
Albumins
Glycoproteins
Salicylic Acid
Mucins
Warfarin
Digitoxin
Mucin-1

Keywords

  • Competitive inhibition
  • Cosalane
  • Gel filtration
  • Protein binding
  • Self-association

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Chemistry(all)
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science

Cite this

Binding of cosalane - A novel highly lipophilic anti-HIV agent - To albumin and glycoprotein. / Kuchimanchi, Kameswara R.; Ahmed, Mahmoud; Johnston, Thomas P.; Mitra, Ashim K.

In: Journal of Pharmaceutical Sciences, Vol. 90, No. 5, 2001, p. 659-666.

Research output: Contribution to journalArticle

Kuchimanchi, Kameswara R. ; Ahmed, Mahmoud ; Johnston, Thomas P. ; Mitra, Ashim K. / Binding of cosalane - A novel highly lipophilic anti-HIV agent - To albumin and glycoprotein. In: Journal of Pharmaceutical Sciences. 2001 ; Vol. 90, No. 5. pp. 659-666.
@article{cad81475caf143f1a7ba7ae4ff28d5ee,
title = "Binding of cosalane - A novel highly lipophilic anti-HIV agent - To albumin and glycoprotein",
abstract = "Cosalane is a potent inhibitor of HIV replication with multiple sites of action. The purposes of this study were to (a) determine the extent and nature of cosalane binding to mucin, α1-acid glycoprotein (AAG), plasma, and human (HSA) and bovine serum (BSA) albumin, and (b) determine the primary site(s) of cosalane binding to HSA. Plasma protein binding of cosalane was studied by a gel filtration technique. Cosalane binding to HSA was also determined in the presence of salicylic acid. Competitive inhibition studies were conducted using warfarin, digitoxin, and diazepam to determine the primary HSA binding site(s) of cosalane. The drug was bound extensively to HSA and BSA and required 500-550 moles to saturate 1 mole of protein. Stoichiometries of cosalane binding to α1-acid glycoprotein (AAG) and mucin were between 30 and 50 mol/mol of either glycoprotein. The binding isotherm deviated from a rectangular hyperbola, suggesting self-association of the ligand. Salicylic acid decreased cosalane binding to HSA by one order of magnitude. Inhibition studies of cosalane to HSA revealed that the compound binds primarily to warfarin site with a Ki of 1.24 ± 0.24 nM. In summary, cosalane binds extensively to serum albumins and to a lesser extent to both AAG and mucin.",
keywords = "Competitive inhibition, Cosalane, Gel filtration, Protein binding, Self-association",
author = "Kuchimanchi, {Kameswara R.} and Mahmoud Ahmed and Johnston, {Thomas P.} and Mitra, {Ashim K.}",
year = "2001",
doi = "10.1002/1520-6017(200105)90:5<659::AID-JPS1022>3.0.CO;2-8",
language = "English (US)",
volume = "90",
pages = "659--666",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Binding of cosalane - A novel highly lipophilic anti-HIV agent - To albumin and glycoprotein

AU - Kuchimanchi, Kameswara R.

AU - Ahmed, Mahmoud

AU - Johnston, Thomas P.

AU - Mitra, Ashim K.

PY - 2001

Y1 - 2001

N2 - Cosalane is a potent inhibitor of HIV replication with multiple sites of action. The purposes of this study were to (a) determine the extent and nature of cosalane binding to mucin, α1-acid glycoprotein (AAG), plasma, and human (HSA) and bovine serum (BSA) albumin, and (b) determine the primary site(s) of cosalane binding to HSA. Plasma protein binding of cosalane was studied by a gel filtration technique. Cosalane binding to HSA was also determined in the presence of salicylic acid. Competitive inhibition studies were conducted using warfarin, digitoxin, and diazepam to determine the primary HSA binding site(s) of cosalane. The drug was bound extensively to HSA and BSA and required 500-550 moles to saturate 1 mole of protein. Stoichiometries of cosalane binding to α1-acid glycoprotein (AAG) and mucin were between 30 and 50 mol/mol of either glycoprotein. The binding isotherm deviated from a rectangular hyperbola, suggesting self-association of the ligand. Salicylic acid decreased cosalane binding to HSA by one order of magnitude. Inhibition studies of cosalane to HSA revealed that the compound binds primarily to warfarin site with a Ki of 1.24 ± 0.24 nM. In summary, cosalane binds extensively to serum albumins and to a lesser extent to both AAG and mucin.

AB - Cosalane is a potent inhibitor of HIV replication with multiple sites of action. The purposes of this study were to (a) determine the extent and nature of cosalane binding to mucin, α1-acid glycoprotein (AAG), plasma, and human (HSA) and bovine serum (BSA) albumin, and (b) determine the primary site(s) of cosalane binding to HSA. Plasma protein binding of cosalane was studied by a gel filtration technique. Cosalane binding to HSA was also determined in the presence of salicylic acid. Competitive inhibition studies were conducted using warfarin, digitoxin, and diazepam to determine the primary HSA binding site(s) of cosalane. The drug was bound extensively to HSA and BSA and required 500-550 moles to saturate 1 mole of protein. Stoichiometries of cosalane binding to α1-acid glycoprotein (AAG) and mucin were between 30 and 50 mol/mol of either glycoprotein. The binding isotherm deviated from a rectangular hyperbola, suggesting self-association of the ligand. Salicylic acid decreased cosalane binding to HSA by one order of magnitude. Inhibition studies of cosalane to HSA revealed that the compound binds primarily to warfarin site with a Ki of 1.24 ± 0.24 nM. In summary, cosalane binds extensively to serum albumins and to a lesser extent to both AAG and mucin.

KW - Competitive inhibition

KW - Cosalane

KW - Gel filtration

KW - Protein binding

KW - Self-association

UR - http://www.scopus.com/inward/record.url?scp=0035029033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035029033&partnerID=8YFLogxK

U2 - 10.1002/1520-6017(200105)90:5<659::AID-JPS1022>3.0.CO;2-8

DO - 10.1002/1520-6017(200105)90:5<659::AID-JPS1022>3.0.CO;2-8

M3 - Article

VL - 90

SP - 659

EP - 666

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 5

ER -